At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Trading 11-13 09:31:34 EST
3.31
-0.02
-0.60%
High3.34Low3.29Vol648.09K
Open3.33D1 Closing3.33Amplitude1.50%
Mkt Cap2.06BTradable Cap2.01BTotal Shares622.76M
T/O2.15MT/O Rate0.11%Tradable Shares605.79M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock
Simply Wall St.  ·  10:26
Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock
Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Decline 7.52%, market reassesses REC-4881 registrational path after prior data-driven rally
Market Focus  ·  11-12 23:00
Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Decline 7.52%, market reassesses REC-4881 registrational path after prior data-driven rally
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump
Market Focus  ·  11-12 22:23
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump
Movement Alert｜Recursion Pharmaceuticals, Inc. Pre-Market Rise 5.07%, REC-4881 Phase 2 Data and Registrational Trial Plan Draw Focus
Market Focus  ·  11-11 21:05
Movement Alert｜Recursion Pharmaceuticals, Inc. Pre-Market Rise 5.07%, REC-4881 Phase 2 Data and Registrational Trial Plan Draw Focus
Recursion Pharmaceuticals Plans to Attend Three Healthcare Investor Conferences
Reuters  ·  11-11 21:03
Recursion Pharmaceuticals Plans to Attend Three Healthcare Investor Conferences
Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says
MT Newswires Live  ·  11-10
Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says
Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation
Simply Wall St.  ·  11-09
Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation
Recursion Stock Gets A Lift From Trial Progress And New Board Chair
Simply Wall St.  ·  11-06
Recursion Stock Gets A Lift From Trial Progress And New Board Chair
Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock Units
Reuters  ·  11-05
Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock Units
Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares
Reuters  ·  11-05
Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares
Recursion Pharmaceuticals Q3 Operating Revenue USD 18.055 Million Vs. IBES Estimate USD 14.8 Million
Reuters  ·  11-03
Recursion Pharmaceuticals Q3 Operating Revenue USD 18.055 Million Vs. IBES Estimate USD 14.8 Million
Recursion Pharmaceuticals Q3 EPS $(0.22), Inline, Sales $18.552M Beat $14.783M Estimate
Benzinga Earnings  ·  11-03
Recursion Pharmaceuticals Q3 EPS $(0.22), Inline, Sales $18.552M Beat $14.783M Estimate
Recursion Pharmaceuticals Q3 Net Loss Narrows More than Expected on Lower Costs
Reuters  ·  11-03
Recursion Pharmaceuticals Q3 Net Loss Narrows More than Expected on Lower Costs
Recursion Pharmaceuticals Q3 Pretax Profit USD -119.011 Million
THOMSON REUTERS  ·  11-03
Recursion Pharmaceuticals Q3 Pretax Profit USD -119.011 Million
Recursion Pharmaceuticals: Expected Cash Runway Extended into 2029; 2026 Cash Operating Expense Guidance < $375 Mln; 2027 < $360 Mln
THOMSON REUTERS  ·  11-03
Recursion Pharmaceuticals: Expected Cash Runway Extended into 2029; 2026 Cash Operating Expense Guidance < $375 Mln; 2027 < $360 Mln
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in Rec-4881 and Rec-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
THOMSON REUTERS  ·  11-03
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in Rec-4881 and Rec-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
Press Release: Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
Dow Jones  ·  11-03
Press Release: Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
New Phase 2 Rec-4881 Data Presented at Cga-IGC Show Deep, Durable Polyp Burden Reductions in Fap, with Activity Across the Gi Tract and in Larger, Higher-Risk Polyps
THOMSON REUTERS  ·  11-03
New Phase 2 Rec-4881 Data Presented at Cga-IGC Show Deep, Durable Polyp Burden Reductions in Fap, with Activity Across the Gi Tract and in Larger, Higher-Risk Polyps
Recursion Pharmaceuticals - no New Safety Signals in Phase 2 Rec-4881; 81% Grade 1/2 Traes, 15% Grade 3, no Grade 4/5 Traes
THOMSON REUTERS  ·  11-03
Recursion Pharmaceuticals - no New Safety Signals in Phase 2 Rec-4881; 81% Grade 1/2 Traes, 15% Grade 3, no Grade 4/5 Traes
Recursion Pharmaceuticals - to Initiate Registrational Trial for Rec-4881 in Second Half of 2027
THOMSON REUTERS  ·  11-03
Recursion Pharmaceuticals - to Initiate Registrational Trial for Rec-4881 in Second Half of 2027

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--